115 related articles for article (PubMed ID: 38862179)
21. Comparison of Aspirin Monotherapy versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting.
Hess NR; Sultan I; Wang Y; Thoma F; Kilic A
Am J Cardiol; 2021 Jun; 148():44-52. PubMed ID: 33667447
[TBL] [Abstract][Full Text] [Related]
22. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
[TBL] [Abstract][Full Text] [Related]
23. Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial.
Krucoff M; Spirito A; Baber U; Sartori S; Angiolillo DJ; Briguori C; Cohen DJ; Collier T; Dangas G; Dudek D; Escaned J; Gibson CM; Han YL; Huber K; Kastrati A; Kaul U; Kornowski R; Kunadian V; Vogel B; Mehta SR; Moliterno D; Sardella G; Shlofmitz RA; Sharma S; Steg PG; Pocock S; Mehran R
Am Heart J; 2024 Jun; 272():11-22. PubMed ID: 38458371
[TBL] [Abstract][Full Text] [Related]
24. Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.
Sandner S; Redfors B; Angiolillo DJ; Audisio K; Fremes SE; Janssen PWA; Kulik A; Mehran R; Peper J; Ruel M; Saw J; Soletti GJ; Starovoytov A; Ten Berg JM; Willemsen LM; Zhao Q; Zhu Y; Gaudino M
JAMA; 2022 Aug; 328(6):554-562. PubMed ID: 35943473
[TBL] [Abstract][Full Text] [Related]
25. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting.
Gasparovic H; Petricevic M; Kopjar T; Djuric Z; Svetina L; Biocina B
Am J Cardiol; 2014 May; 113(10):1660-7. PubMed ID: 24666617
[TBL] [Abstract][Full Text] [Related]
26. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
Vogel B; Baber U; Cohen DJ; Sartori S; Sharma SK; Angiolillo DJ; Farhan S; Goel R; Zhang Z; Briguori C; Collier T; Dangas G; Dudek D; Escaned J; Gil R; Han YL; Kaul U; Kornowski R; Krucoff MW; Kunadian V; Mehta SR; Moliterno D; Ohman EM; Sardella G; Witzenbichler B; Gibson CM; Pocock S; Huber K; Mehran R
JAMA Cardiol; 2021 Sep; 6(9):1032-1041. PubMed ID: 33991416
[TBL] [Abstract][Full Text] [Related]
27. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Chichareon P; Modolo R; Kerkmeijer L; Tomaniak M; Kogame N; Takahashi K; Chang CC; Komiyama H; Moccetti T; Talwar S; Colombo A; Maillard L; Barlis P; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Valgimigli M; Windecker S; Onuma Y; Mehran R; Serruys PW
JAMA Cardiol; 2020 Jan; 5(1):21-29. PubMed ID: 31693078
[TBL] [Abstract][Full Text] [Related]
28. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
29. Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial.
Ono M; Hara H; Kawashima H; Gao C; Wang R; Wykrzykowska JJ; Piek JJ; Garg S; Hamm C; Steg PG; Valgimigli M; Windecker S; Vranckx P; Onuma Y; Serruys PW
EuroIntervention; 2022 Aug; 18(5):e377-e388. PubMed ID: 35260381
[TBL] [Abstract][Full Text] [Related]
30. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
Kim C; Hong SJ; Shin DH; Kim BK; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Am Heart J; 2019 Jun; 212():45-52. PubMed ID: 30933857
[TBL] [Abstract][Full Text] [Related]
31. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Hara H; van Klaveren D; Takahashi K; Kogame N; Chichareon P; Modolo R; Tomaniak M; Ono M; Kawashima H; Wang R; Gao C; Niethammer M; Fontos G; Angioi M; Ribeiro VG; Barbato E; Leandro S; Hamm C; Valgimigli M; Windecker S; Jüni P; Steg PG; Verbeeck J; Tijssen JGP; Sharif F; Onuma Y; Serruys PW;
Circ Cardiovasc Qual Outcomes; 2020 Aug; 13(8):e006660. PubMed ID: 32762446
[TBL] [Abstract][Full Text] [Related]
32. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Verdoia M; Nardin M; Gioscia R; Negro F; Marcolongo M; Suryapranata H; Kedhi E; De Luca G;
Vascul Pharmacol; 2020 Sep; 132():106765. PubMed ID: 32681888
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
Kawashima H; Tomaniak M; Ono M; Wang R; Hara H; Gao C; Takahashi K; Sharif F; Thury A; Suryapranata H; Walsh S; Cotton J; Carrie D; Sabate M; Steinwender C; Leibundgut G; Wykrzykowska J; de Winter RJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
Am J Cardiol; 2021 Jan; 138():1-10. PubMed ID: 33065080
[TBL] [Abstract][Full Text] [Related]
34. Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design.
Gao C; Zhu B; Liu J; Jiang Z; Hu T; Wang Q; Liu Y; Yuan M; Li F; Zhang R; Xia J; Onuma Y; Wang D; Serruys P; Tao L;
BMC Cardiovasc Disord; 2024 Jan; 24(1):62. PubMed ID: 38245724
[TBL] [Abstract][Full Text] [Related]
35. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.
Wang Y; Chen W; Lin Y; Meng X; Chen G; Wang Z; Wu J; Wang D; Li J; Cao Y; Xu Y; Zhang G; Li X; Pan Y; Li H; Zhao X; Liu L; Lin J; Dong K; Jing J; Johnston SC; Wang D; Wang Y;
BMJ; 2019 Jun; 365():l2211. PubMed ID: 31171523
[TBL] [Abstract][Full Text] [Related]
36. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
[TBL] [Abstract][Full Text] [Related]
37. Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial.
Benedetto U; Altman DG; Gerry S; Gray A; Lees B; Flather M; Taggart DP;
Eur J Cardiothorac Surg; 2017 Sep; 52(3):456-461. PubMed ID: 28387790
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
Baber U; Jang Y; Oliva A; Cao D; Vogel B; Dangas G; Sartori S; Spirito A; Smith KF; Branca M; Collier T; Pocock S; Valgimigli M; Kim BK; Hong MK; Mehran R
Circulation; 2024 Feb; 149(8):574-584. PubMed ID: 37870970
[TBL] [Abstract][Full Text] [Related]
39. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
Bhatt DL; Fox K; Harrington RA; Leiter LA; Mehta SR; Simon T; Andersson M; Himmelmann A; Ridderstråle W; Held C; Steg PG;
Clin Cardiol; 2019 May; 42(5):498-505. PubMed ID: 30788847
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Study).
Pufulete M; Harris J; Sterne JAC; Johnson TW; Lasserson D; Mumford A; Doble B; Wordsworth S; Benedetto U; Rogers CA; Loke Y; Pithara C; Redwood S; Reeves BC
BMJ Open; 2019 Jun; 9(6):e029388. PubMed ID: 31167875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
